Research Reports | Market Assessment
March 2018

Psoriatic Arthritis | Treatment Algorithms | Claims Data Analysis | US | 2018

MARKET OUTLOOK

Treatment for PsA typically begins with a cDMARD, but often progresses to a tsDMARD or bDMARD within two years. TNFi are the mainstay of treatment for recently treated patients, but newer therapies including two IL-17 inhibitors have a growing market share. Persistency and compliance are highest for Remicade, but Enbrel and Humira continue to capture the largest portion of the bDMARD market.

QUESTIONS ANSWERED

  • How long do patients wait between a diagnosis and an initial prescription? How fast do newly diagnosed patients progress through lines of therapy?
  • Where in the treatment algorithm will new therapies such as Taltz, Xeljanz, and Orencia fall?
  • What changes have taken place in the treatment algorithm within the last three years? What therapies have a growing or shrinking market share? 
  • How compliant are PsA patients with their prescribed medication? What medications have the highest persistency?
Login to access report
Back to all Market Assessment reports
Login to access report

launch Related Market Assessment Reports